Liposomes Market 2022
According to PMR, the global liposomes market was valued at US$ 6.5 Bn in 2022, and is expected to expand at a CAGR of around 7% during the forecast period (2022–2030).
The pharmaceutical industry is making use of AI for discovering new-fangled drugs. January 2020 witnessed the invention of the very first drug molecule using AI, whose patent lay with Japanese and British scientists. The medicine is being used for treating OCD (obsessive-compulsive disorder). Likewise, several promising formulas are being discovered as an outcome of AI-enabled lab experimenting. This would be how the pharmaceutical arm of the healthcare vertical look shortly.
Get Going With Sample Of Liposomes Market Report@https://www.persistencemarketresearch.com/samples/16546
Liposomes are a novel system widely used in the field of drug delivery, gene delivery, medical imaging, and model cell membrane biology. Stealth liposome technology, DepoFoam technology, and non-PEGylated liposomal technology are gaining significant adoption in the development of liposome-based products. Growing research & development activities for the delivery of anti-fungal, anti-cancer, anti-inflammatory drugs, and therapeutic genes are boosting the demand for liposome formulations.
Liposomes have the ability to overcome the limitations of conventional therapy and provide benefits in various therapeutic applications, ranging from cancer to pain management. Encapsulation of drugs in liposomes improves the therapeutic indices of various agents.
Company Profiles:
- Pfizer Inc.
- Novartis AG
- Teva Pharmaceutical Industries Ltd
- Johnson & Johnson
- Dr. Reddy’s Laboratories Ltd.
- Sun Pharma Industries Ltd
- Baxter AG
- Sanofi SA
- Bristol Myers Squibb
- Mylan NV
- GlaxoSmithKline Plc.
- Creative Biolabs
- Precision NanoSystems Inc.
- SkyePharma Inc.
- Luye Pharma Group
- Encapsula NanoSciences LLC
- Nanovex Biotechnologies SL
- Gilead Sciences, Inc.
- Avanti Polar Lipids, Inc.
- Fujifilm Holdings Corporation
Switch over to the “Methodology” tab@ https://www.persistencemarketresearch.com/methodology/16546
Key Takeaways from Liposomes Market Study
- Formulated liposomes occupied nearly 68% of the market value share in the liposomes market in 2019, owing to increasing adoption of liposome-based drug formulations. Doxorubicin and paclitaxel formulated liposomes contributed more than three-fifth of market value share in the global liposomes market.
- Drug delivery applications accounted the highest market value share in the global liposomes market, on the back of rising demand for nanotechnology drug delivery. The cancer drug delivery application segment is expected to progress at the highest growth rate, due to increasing R&D activities to develop drugs for cancer.
- Distributional sales hold a major share in the global liposomes market, owing to the growing demand for formulated liposomal drugs.
- North America holds a prominent revenue share in the global liposomes market, as a result of rising prevalence of cancer and fungal diseases in the region. However, the liposomes market in East Asia is projected to flourish at the highest growth rate, owing to increasing pharmaceutical expenditure in the region.
- The race for liposomal vaccine development to combat the ongoing COVID-19 pandemic is a catalyst for the growth of the global liposomes market.
“Rising demand for liposomal formulations and vaccines, and increasing research activities in the field of biomolecules and gene delivery, are expected to favor the growth of the liposomes market,” says a PMR analyst.
Go To “Purchase Now” To Decipher The Competitive Analysis In Our Liposomes Market Report@ https://www.persistencemarketresearch.com/checkout/16546
Product Portfolio Expansion and Regulatory Approval – Key Strategies of Leading Liposome Manufacturers
Manufacturers in the liposomes market are focusing on product portfolio expansion and new product launches. For instance, in September 2017, Novartis received EU approval for the Rydapt® (midostaurin) drug for FLT3-mutated acute myeloid leukaemia (AML) and three types of advanced systemic mastocytosis. Manufacturers are focusing on acquiring regulatory approval in different countries for the expansion of product sales. For instance, in October 2017, GlaxoSmithKline Plc. declared that the US Food and Drug Administration approved Shingrix (zoster vaccine recombinant, adjuvanted) for the prevention of shingles in adults aged 50 years and above.
Key Questions Answered in PMR’s Liposomes Market Report
- Which regions will continue to remain the most profitable regional markets for liposomes market players?
- Which factors will induce a change in the demand for liposomes during the assessment period?
- What are the different opportunities available for emerging players in the liposomes market?
- How are supply-side and demand-side drivers impacting the liposomes market?
- How will changing trends impact the liposomes market?
- How can market players capture the low-hanging opportunities in the liposomes market in developed regions?
- Which companies are leading the liposomes market?
- What are the winning strategies of stakeholders in the liposomes market to upscale their position in this landscape?
About Us: Persistence Market Research
Contact Us:
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com